Skip to main content
. 2021 Dec 12;2021:3420168. doi: 10.1155/2021/3420168

Table 4.

The relationship between disease and key proteins.

Key proteins Effect in disease Related diseases FDA-approved inhibitor (company) References
Caspase-8 Mediator Inflammation and disease in rodent malaria None [52]
RIPK1 Activation of RIPK1 Skin diseases, including melanoma, psoriasis, and systemic lupus erythematosus Sunitinib (Pfizer), Pazopanib (GSK, Novartis) [53, 54]
RIPK3 Mediator Sepsis-associated organ injury and chronic lung diseases Dabrafenib (GSK, Novartis) [54, 55]